We are live on ! Find out more
CRNX icon

Crinetics Pharmaceuticals
CRNX

80 hedge funds and large institutions have $465M invested in Crinetics Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 27 increasing their positions, 26 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

8% more capital invested

Capital invested by funds: $429M → $465M (+$36.1M)

4% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 26

0.92% more ownership

Funds ownership: 92.42% → 93.35% (+0.92%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

6% less funds holding

Funds holding: 85 → 80 (-5)

45% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 11

Holders
80
Holders Change
-5
Holders Change %
-5.88%
% of All Funds
1.4%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
6
Increased
27
Reduced
26
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
DCM
Driehaus Capital Management
Illinois
+$8.52M
2
SFM
Sphera Funds Management
Israel
+$4.41M
3
OM
Opaleye Management
Massachusetts
+$2.91M
4
Deutsche Bank
Deutsche Bank
Germany
+$1,000K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$867K

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$7.96M
2
EAM
Eventide Asset Management
Massachusetts
-$2.46M
3
VC
Vivo Capital
California
-$1.89M
4
Citadel Advisors
Citadel Advisors
Florida
-$661K
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$497K
Name Holding Trade Value Shares
Change 		Change in
Stake
NLVP
26
New Leaf Venture Partners
New York
$2.15M – – –
N
27
Nuveen
North Carolina
$1.98M -$119K -7,655 -6%
Goldman Sachs
28
Goldman Sachs
New York
$1.87M -$90.4K -5,830 -5%
Deutsche Bank
29
Deutsche Bank
Germany
$1.3M +$1,000K +64,495 +315%
Victory Capital Management
30
Victory Capital Management
Texas
$1.27M +$476K +30,720 +59%
Jacobs Levy Equity Management
31
Jacobs Levy Equity Management
New Jersey
$1.12M -$240K -15,488 -17%
JP Morgan Chase
32
JP Morgan Chase
New York
$1.03M -$185K -11,904 -15%
Dimensional Fund Advisors
33
Dimensional Fund Advisors
Texas
$1M +$648K +41,825 +175%
AA
34
ALPS Advisors
Colorado
$910K +$1.95K +126 +0.2%
Two Sigma Investments
35
Two Sigma Investments
New York
$885K +$62.5K +4,033 +7%
California Public Employees Retirement System
36
California Public Employees Retirement System
California
$837K -$78.2K -5,048 -8%
T. Rowe Price Associates
37
T. Rowe Price Associates
Maryland
$747K -$497K -32,037 -40%
California State Teachers Retirement System (CalSTRS)
38
California State Teachers Retirement System (CalSTRS)
California
$623K – – –
State of Wisconsin Investment Board
39
State of Wisconsin Investment Board
Wisconsin
$590K – – –
Swiss National Bank
40
Swiss National Bank
Switzerland
$575K +$21.7K +1,400 +4%
Two Sigma Advisers
41
Two Sigma Advisers
New York
$524K +$181K +11,700 +52%
Norges Bank
42
Norges Bank
Norway
$513K +$521K +33,600 New
RhumbLine Advisers
43
RhumbLine Advisers
Massachusetts
$434K -$36.7K -2,370 -8%
AllianceBernstein
44
AllianceBernstein
Tennessee
$410K -$17K -1,100 -4%
New York State Common Retirement Fund
45
New York State Common Retirement Fund
New York
$379K – – –
Barclays
46
Barclays
United Kingdom
$375K +$212K +13,674 +125%
VEA
47
Virtus ETF Advisers
New York
$334K +$6.12K +395 +2%
SMH
48
Sanders Morris Harris
Texas
$306K – – –
HTC
49
Hershey Trust Company
Pennsylvania
$302K – – –
Manulife (Manufacturers Life Insurance)
50
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$265K +$1.18K +76 +0.4%
1
2
3 4

CRNX Hedge Fund Activity: Q1 2021 in Review

80 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Crinetics Pharmaceuticals (CRNX) for Q1 2021, worth a combined $465M — up 8.4% from $429M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of CRNX and 6 opened new positions — a net loss of 5 holders — while 26 trimmed existing stakes and 27 added.

The largest buyer was Driehaus Capital Management, adding an estimated $8.52M. The largest seller was RA Capital Management, exiting entirely with an estimated $7.96M sold.

  • 80 institutional investors held Crinetics Pharmaceuticals (CRNX) as of Q1 2021, down from 85 in Q4 2020.
  • Funds reported $465M of Crinetics Pharmaceuticals stock for Q1 2021, up 8.4% quarter-over-quarter.
  • 6 funds opened new Crinetics Pharmaceuticals positions in Q1 2021 and 11 closed out, a net change of -5 holders.
  • The largest Crinetics Pharmaceuticals buyer in Q1 2021 was Driehaus Capital Management, an estimated $8.52M added.
  • The largest Crinetics Pharmaceuticals seller in Q1 2021 was RA Capital Management, an estimated $7.96M sold.

Based on aggregated 13F filings for Q1 2021.